SCHEMBL30584782

SCHEMBL30584782

N#Cc1cccc(-c2noc(N3CCC(C(=O)O)CC3)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.62
▸ PDE4D Q08499 3/20 0.56
▸ PDE4A P27815 2/20 0.56
▸ PDE4B Q07343 2/20 0.56
▸ PDE4C Q08493 2/20 0.56
▸ NOTUM Q6P988 1/20 0.54
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GRM5 P41594 1/20 0.46
▸ TP53 P04637 2/20 0.45
▸ SCD O00767 1/20 0.45
▸ SCD5 Q86SK9 1/20 0.45
▸ S1PR1 P21453 1/20 0.43
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA5 P30532 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CPT2 P23786 1/20 0.42
▸ CPT1A P50416 1/20 0.42
▸ S1PR3 Q99500 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25433010 1.00 MAPT (0.62) MAPTPDE4DPDE4APDE4BPDE4C
SCHEMBL30584785 1.00 MAPT (0.62) MAPTPDE4DPDE4APDE4BPDE4C
SCHEMBL30584777 0.88 MAPT (0.61) MAPTMEN1KMT2AGRM5TP53
SCHEMBL25433079 0.88 MAPT (0.61) MAPTMEN1KMT2AGRM5TP53
SCHEMBL25433461 0.86 MAPT (0.58) MAPTMEN1KMT2ATP53LMNA
SCHEMBL25435216 0.83 GRM5 (0.53) MAPTNOTUMMEN1KMT2AGRM5
SCHEMBL30584813 0.83 GRM5 (0.53) MAPTPDE4DPDE4APDE4BPDE4C
SCHEMBL25402964 0.83 GRM5 (0.53) MAPTPDE4DPDE4APDE4BPDE4C
SCHEMBL30584787 0.83 GRM5 (0.53) MAPTNOTUMMEN1KMT2AGRM5
SCHEMBL25401997 0.80 MEN1 (0.65) MAPTPDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 MAPT 2999/4885PDE4D 2494/4885PDE4A 3002/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MAPT 2999/4885PDE4D 2494/4885PDE4A 3002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback